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The current standard treatment for AIDS-associated cerebral 
toxoplasmosis is pyrimethamine plus sulfadiazine (PS). 
PS has been associated with high toxicity rates.1,2  Several 
alternative therapies, principally used in patients intolerant to 
sulfonamides, have been reported to be effective: clindamycin 
plus pyrimethamine,3 clarithromycin plus pyrimethamine,4 
and atovaquone.5  Folinic acid must be co-administered 
with pyrimethamine to prevent bone marrow suppression. 
Co-trimoxazole (trimethoprim plus sulfamethoxazole)(TMP-
SMX) had a similar efficacy to PS for treating AIDS-associated 
cerebral toxoplasmosis and was better tolerated in a 
retrospective study,1 followed by a randomised controlled trial 
conducted by the same group.6 TMP-SMX is more affordable 
than the other anti-toxoplasmosis therapies, particularly as 
co-administration with folinic acid is not required.  There are 
limited published data on the use of TMP-SMX in cerebral 
toxoplasmosis in sub-Saharan Africa, where efficacy and 
adverse events may be different from those reported in other 
populations. A study examined the efficacy of TMP-SMX in 20 
South African AIDS patients with cerebral toxoplasmosis, but 
it had no comparator arm and non-responders were excluded 
from the analysis.7   
In our centre the treatment policy for AIDS-associated 
cerebral toxoplasmosis was changed from PS to TMP-SMX 
after the withdrawal of sulfadiazine from the South African 
market. In this retrospective study we compared the clinical 
outcomes and tolerability of PS and TMP-SMX. Although 
glucocorticoids are often added as adjuvant therapy in 
clinical practice, a retrospective study concluded that neither 
beneficial nor harmful effects could be attributed to their use.2 
We  therefore also examined the role of glucocorticoids in the 
management of toxoplasmosis. 
Patients and methods 
We reviewed the records of all HIV-infected adult patients 
with a diagnosis of cerebral toxoplasmosis at discharge.  They 
had been admitted to Groote Schuur Hospital, a teaching 
hospital affiliated to the University of Cape Town, between 
1992 and 2003. Patients were identified from an electronic 
database of hospital discharge diagnoses. Sulfadiazine has been 
unavailable in South Africa since 1999. Patients treated  from 
1992 to 1998 received PS, while those treated during 1999 - 
2003 received TMP-SMX. The following diagnostic criteria 
were used for cerebral toxoplasmosis: multiple intracranial 
mass lesions (demonstrated on either MRI or CT scan), or a 
single lesion supported by positive toxoplasmosis serology, or 
a single lesion with an improvement in clinical or radiological 
parameters in response to treatment. 
Patients were stratified on entry according to the British 
Medical Research Council criteria as modified by Thwaites 
et al.:8 grade I Glasgow Coma Scale (GCS) of 15 with no focal 
neurological signs; grade II GCS of 11 - 14, or 15 with focal 
neurological signs; and grade III GCS of 10 or less. Clinical 
outcomes at discharge were considered only for the first 
admission for toxoplasmosis. Outcomes were categorised as 
complete recovery, disability or death. Disability was defined 
as persistent neurological sequelae, mental handicap or 
uncontrolled seizures at discharge.
Stata 8.0 was used to describe and compare baseline 
characteristics and outcomes in the treatment groups, using 
Fisher’s exact test for categorical data and the Kruskal-Wallis 
test for continuous data. The study was approved by the 
Research Ethics Committee of the University of Cape Town.
Results
Of the 58 patients treated for presumed cerebral toxoplasmosis 
between 1992 and 2003, 43 fulfilled our diagnostic criteria for 
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the condition. Table I summarises the baseline characteristics, 
clinical outcomes and adverse events by antimicrobial 
treatment. The baseline characteristics were similar for both 
groups, except for a slight age difference, which is unlikely to 
be clinically significant. There was no difference in the clinical 
outcomes between the treatment groups at discharge. There 
was a trend towards more frequent renal impairment after 
treatment with PS  than with TMP-SMX (3/18 v. 0/25; p = 
0.066). Twenty-six patients received adjunctive glucocorticoids 
(Table II). There were no significant differences in the level of 
consciousness (p = 0.139) and CD4 count (p = 0.43) of those 
who received glucocorticoids compared with those who did 
not, but there was a trend towards an increased risk of death 
among patients who received glucocorticoids (6/26 v. 0/17; p =  
0.066). 
Discussion
In our study it was found that there was no difference between 
TMP-SMX and PS in terms of the clinical outcomes of full 
recovery, disability and death. There was a trend towards more 
frequent renal impairment in the PS group. Haematological 
toxicity was not significantly different between the two groups, 
probably because we routinely prescribed folinic acid for all 
patients on PS. These findings are in keeping with the results of 
a randomised controlled trial (N = 77) of TMP-SMX compared 
with PS for AIDS-associated cerebral toxoplasmosis, which 
concluded that there was no difference in clinical efficacy 
between the two treatments, and that TMP-SMX was better 
tolerated.6 
Cerebral toxoplasmosis is generally treated empirically in 
AIDS patients with compatible neuro-imaging studies and 
positive serology. A South African study demonstrated on 
biopsy or aspiration that toxoplasmosis was the commonest 
cause of intracranial mass lesions in HIV-infected adults.9 
Therefore we are confident that subjects fulfilling our inclusion 
criteria almost certainly had cerebral toxoplasmosis. 
Clinicians prescribe adjunctive glucocorticoids for cerebral 
oedema frequently surrounding intracranial mass lesions 
of toxoplasmosis. These drugs were prescribed to 60% of  
patients in our study. However, there is no evidence that 
adjunctive glucocorticoids improve outcome.  They can be 
potentially harmful and can mask alternative diagnoses. This 
is particularly important given that the diagnosis of cerebral 
toxoplasmosis is generally made in response to empiric 
therapy. Alternative diagnoses in AIDS patients  include 
tuberculomas, cryptococcomas and lymphomas – all of which 
may improve transiently with glucocorticoids if surrounding 
cerebral oedema is present. 
In our study the trend towards more deaths in the 
glucocorticoid group is of concern, as these drugs appear to 
be widely used. Patients in the glucocorticoid group were 
comparable with those who did not receive glucocorticoids 
with regard to their neurological baseline characteristics and 
CD4 counts. Until the role and safety of glucocorticoids in 
Table I. Baseline characteristics and treatment response in 43 HIV patients with cerebral toxoplasmosis by antimicrobial 
treatment group
     Pyrimethamine-sulfadiazine  Co-trimoxazole
     (N = 18)    (N = 25)   p
Demographics   
Median age (IQR)   34 (32 - 41)   31 (27 - 34)  0.025
Male      9 (50%)    9 (36%)   0.359
Clinical parameters   
Level of consciousness 
Grade I        3 (17%)    2 (8%)   0.634
Grade II       15 (83%)    23 (92%)   0.634
Seizures    10 (56%)    17 (68%)   0.405
Concurrent tuberculosis    4 (22%)    5 (20%)   1.000
Laboratory parameters   
Median CD4 count (106/l) (IQR) (N = 23)         43 (8 - 77)    14 (4 - 25)   0.226
Median haemoglobin (g/dl) (IQR) (N = 41)   11 (8.8 - 13.7)   10.4 (9.4 - 11.7)  0.560
Positive toxoplasmosis serology (N = 27) 12/13 (92%)   14/14 (100%)  0.290
Outcome      
Full recovery     7 (39%)    11 (44%)   0.738
Disability      9 (50%)    10 (40%)   0.736
Death      2 (11%)    4 (16%)   1.000
Adverse events   
Renal dysfunction    3 (17%)    0 (0%)   0.066
Liver impairment    2 (11%)    0 (0%)   0.169
Total          4 (22%)    1 (4%)   0.144
IQR = interquartile range.
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the management of cerebral toxoplasmosis are clarified in 
a controlled trial, we would advocate using them only for 
toxoplasmosis patients with life-threatening compression 
caused by oedema surrounding intracranial mass lesions.
Our study has important limitations. The small sample size 
limits our power and the retrospective design does not allow 
for control of all confounders. 
Authors’ roles: NC and GM conceived and designed the study; 
JA drafted the paper; JA, KB and GM analysed and interpreted 
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Table II. Baseline characteristics and treatment response in 43 HIV patients with cerebral toxoplasmosis by adjuvant 
glucocorticoid treatment group 
                 Adjunctive glucocorticoids 
     Yes (N = 26)  No (N = 17)  p
Demographics   
Median age (IQR)   32 (27 - 37)  34 (31 - 35)  0.129
Male      11 (42%)   7 (44%)   0.941
Clinical parameters
Level of consciousness    
Grade I        5 (19%)   0 (0%)   0.139
Grade II       21 (81%)   17 (100%)   0.139
Seizures     18 (69%)   9 (53%)   0.280
Concurrent tuberculosis    4 (24%)   5 (19%)   1.000
Laboratory parameters    
Median CD4 count (106/l) (IQR) (N = 23) 14 (4 - 38)   25.5 (8 - 75)  0.403
Median haemoglobin (g/dl) (IQR) (N = 41) 10.1 (9 - 11.55)  11 (9.1 - 13.7)  0.218
Positive toxoplasmosis serology (N = 27) 14/14 (100%)  12/13 (92%)  0.481
By treatment group   
TMP-SMX     18 (69%)   7 (41%)   0.068
Outcome    
Full recovery     10 (39%)   8 (47%)   0.576
Disability      10 (39%)   9 (53%)   0.350
Death      6 (30%)   0 (0%)   0.066
IQR= interquartile range.
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